Stenocare A/S provided revenue guidance for the third quarter, fourth quarter, and full year of 2022. This enables the company to realize sales of prescription-based products to patients in Denmark, in Sweden (already active) and in the UK this year, with a gradual build-up during the year and with the majority of the uptake in sales expected to materialize in the third quarter and fourth quarter of 2022

By the end of the year the expected sales run rate (calculated as Fourth Quarter times 4) is set at DKK 15 million to DKK 20 million, up from total sales in 2021 of DKK 1.9 million.